000 04260nam a22003615i 4500
001 235378
003 ES-VaUE
005 20221220020701.0
007 cr nn 008mamaa
008 100301s2001 xxu| s |||| 0|eng d
020 _a9781592591145
024 7 _a10.1385/1592591140
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
245 1 0 _aImmunotoxin Methods and Protocols
_cedited by Walter A. Hall.
250 _a1st edition 2001
264 1 _aTotowa, NJ
_bHumana Press
_c2001
300 _a1 recurso en línea (XI, 297 páginas)
_b
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aMethods in Molecular Biology
_x1940-6029
_v166
505 0 _aImmunotoxin Construction and Development -- Development and Activities of the BR96-Doxorubicin Immunoconjugate -- CD7-Specific Single Chain Fv Immunotoxins -- Recombinant Fusion Toxins Directed Against the Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Receptor -- Synthesis of Monensin Derivatives and Their Effect on the Activity of Ricin A-Chain Immunotoxins -- Purification and Conjugation of Type 1 Ribosome-Inactivating Proteins -- Comparison of Immunotoxins Bearing a Single Saporin Molecule with Multiple Toxin Conjugates -- Modulation of Growth Factor Receptor Expression by Irradiation for Immunotoxin Targeting -- Quantification of Immunotoxin Number for Complete Therapeutic Response -- In Vitro Studies of Ricin A-Chain-Induced Vascular Leak Syndrome -- Oncologic Applications of Immunotoxins -- Immunotoxin Treatment of Brain Tumors -- Cytotoxins Directed at Interleukin-4 Receptors as Therapy for Human Brain Tumors -- Bispecific Monoclonal Antibodies for the Targeting of Type I Ribosome-Inactivating Proteins Against Hematological Malignancies -- Tyrosine Kinase Inhibitors Against EGF Receptor-Positive Malignancies -- Targeting Tumor Vasculature Using VEGF-Toxin Conjugates -- Gene Therapy With Immunotoxins -- Alternative Applications of Immunotoxins -- Effects of Selective Immunotoxic Lesions on Learning and Memory -- Targeting Toxins to Neural Antigens and Receptors -- In Vivo Testing of Anti-HIV Immunotoxins.
520 _aMore potent and selective for killing cancer cells than chemotherapy, immunotoxins constitute a new class of human therapeutics that have widespread applications and a potential that has not yet been fully recognized. In Immunotoxin Methods and Protocols, leading experts from laboratories around the world describe in step-by-step detail their cutting-edge methods for developing and applying these powerful proteins. The conjugates created by these researchers contain entire monoclonal antibodies, single chain antibody fragments, and cytokines as their carrier ligands. Their toxic portion can include such conventional chemotherapeutics as doxirubicin, such ribosome-inactivating proteins as the ricin A chain or saporin, or such bacterial toxins as diptheria toxin. Also described are a variety of applications that demonstrate the versatility of these agents, including the treatment of primary malignant brain tumors, the generation of selective brain lesions to localize critical functions, and the targeting of the AIDS virus. Each readily reproducible method is optimized for experimental success with hands-on instructions, invaluable notes on pitfalls to avoid, and informative explanations of why certain steps are necessary. Authoritative and highly practical, Immunotoxin Methods and Protocols provides today's cancer researchers, neuroscientists, and oncologists with state-of-the-art tools for exploring these powerful biological agents and their rapidly increasing applications.
700 1 _aHall, Walter A
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9781617371837
776 0 8 _iPrinted edition:
_z9780896037755
776 0 8 _iPrinted edition:
_z9781489942234
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592591140
_z(usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
988 _aSpringer_Protocols_2001
999 _c235378
_d235378